The syncardia 70cc temporary total artificial heart (tah-t) is an implantable pulsatile biventricular replacement device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation systems.The syncardia 70cc tah-t is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.The syncardia tah-t system is intended for use inside and outside the hospital.Investigation summary: intermacs patient registry data collected between april 1, 2014 and september 30, 2017 regarding adverse events was retrospectively reviewed.Patients were de-identified therefore a one-to-one correlation could not be made between the patient and the lot number of the implanted tah-t.These events were assessed and are being reported in response to an update to the mdr complaint sources.With a review of the available information, there is no evidence of a device malfunction or performance issues that would impact the reported events.Possible clinical factors that may have contributed to these events include the patients pre-existing history and related comorbidities, the progression of their underlying disease, issues related to the therapeutic use of anticoagulants, antiplatelet medications and the patient's complex post-operative course.There are possible patient, pharmacological and procedural factors that may have contributed to these events.This device is used for treatment, not diagnosis.If new or additional information is received in the future, syncardia will file a follow-up mdr.(b)(4) (b)(6).
|
While supported by the tah-t, the patient experienced the following adverse events as defined by intermacs: 124 days post implant - infection/location: pump/related - drive line/type: bacterial, 187 days post implant - infection/location: pump/related - drive line/type: bacterial, 12 days post implant - respiratory failure, 84 days post implant - infection/location: positive blood cultures/type: bacterial, 31 days post implant - bleeding, 40 days post implant - bleeding, 1 day post implant - neurological dysfunction - seizure, 63 days post implant - other sae, 122 days post implant - bleeding, 122 days post implant - respiratory failure, 191 days post implant - bleeding, 38 days post implant - psychiatric episode, 119 days post implant - psychiatric episode, 194 days post implant - device malfunction and/or pump thrombosis, 194 days post implant - respiratory failure, 1 day post implant - renal dysfunction, 198 days post implant - infection/location: mediastinum/type: bacterial, 198 days post implant - wound dehiscence.The patient subsequently received a heart transplant after 218 days of tah-t support.
|